Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...
Travere Therapeutics stock jumps 37% after the FDA expands Filspari's use to a second rare kidney disease, boosting its market reach and treatment potential.
The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis ...
Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce ...
Travere Therapeutics (TVTX) stock and Ligand Pharmaceuticals (LGND) stock gain on FDA label expansion for Filspari. Read more ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...
The U.S. Food and Drug Administration has approved the expanded use of Travere Therapeutics' drug to treat a rare kidney ...
Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.
Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...
Investor's Business Daily on MSN
Travere Therapeutics sees its composite rating rise to 97
Travere Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 94 to 97.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results